Muscular dystrophy gene therapy (University of Pennsylvania/Genovo)

N/A

Report date: 2023/10/26 16:21:24

Base Information

Drug NameMuscular dystrophy gene therapy (University of Pennsylvania/Genovo)
Drug Alias NameAAV9-CMV-microutrophin
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionDystrophin pre-mRNA modulators
TargetsDystrophin pre-mRNA
Therapy Area/IndicationsMuscular Dystrophies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of PennsylvaniaGenovo
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenovoUniversity Of Pennsylvania
Active IndicationsN/A
Inactive IndicationsMuscular Dystrophies

Other Information

ATC CodeN/A
Related LinksN/A